Literature DB >> 21150789

Whole-heart coronary magnetic resonance angiography at 1.5 Tesla: does a blood-pool contrast agent improve diagnostic accuracy?

Moritz Wagner1, Roberta Rösler, Alexander Lembcke, Craig Butler, Marc Dewey, Michael Laule, Alexander Huppertz, Carsten Schwenke, Carsten Warmuth, Matthias Rief, Bernd Hamm, Matthias Taupitz.   

Abstract

OBJECTIVES: To evaluate the impact of the blood-pool contrast agent gadofosveset trisodium on diagnostic accuracy of whole-heart coronary magnetic resonance angiography (CMRA) at 1.5 Tesla.
MATERIALS AND METHODS: Thirty consecutive patients with suspected coronary artery disease underwent free-breathing whole-heart CMRA at 1.5 Tesla. CMRA was performed with a T2-prepared steady-state free precession sequence (unenhanced CMRA) and an inversion-recovery-prepared steady-state free precession sequence after administration of gadofosveset trisodium (contrast-enhanced CMRA). Two readers independently performed a per-segment evaluation of CMRA (8 proximal and mid coronary segments) for detection of significant stenosis (≥50%) using invasive coronary angiography as reference. Disagreement was settled by consensus reading and interobserver variability was assessed using an unweighted kappa statistic.
RESULTS: Whole-heart CMRA was successfully performed in 27 patients. The percentage of assessable segments was significantly lower on unenhanced CMRA compared with contrast-enhanced CMRA (Reader 1: 79% [170/216] vs. 89% [192/216], respectively; Reader 2: 73% [157/216] vs. 87% [188/216], respectively; P < 0.001). Intention-to-diagnose analysis of the consensus reading yielded sensitivity, specificity, and diagnostic accuracy of unenhanced versus contrast-enhanced CMRA as follows: 73.1% versus 73.1% (P = 1.0), 68.3% versus 80.2% (P = 0.002), and 68.9% versus 79.3% (P = 0.004), respectively. The kappa value for interobserver agreement was 0.61 (95% confidence interval = 0.50-0.72) for unenhanced CMRA and 0.72 (95% confidence interval = 0.62-0.82) for contrast-enhanced CMRA.
CONCLUSIONS: The blood-pool contrast agent gadofosveset trisodium increased the number of assessable coronary segments on whole-heart CMRA in comparison to unenhanced whole-heart CMRA. The impact of gadofosveset trisodium on diagnostic accuracy, however, was only minor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21150789     DOI: 10.1097/RLI.0b013e3181fac6ef

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  6 in total

1.  Combined blood pool and extracellular contrast agents for pediatric and young adult cardiovascular magnetic resonance imaging.

Authors:  Joyce T Johnson; Joshua D Robinson; Jie Deng; Cynthia K Rigsby
Journal:  Pediatr Radiol       Date:  2016-08-30

2.  Vascular Imaging With Ferumoxytol as a Contrast Agent.

Authors:  Michael D Hope; Thomas A Hope; Chengcheng Zhu; Farshid Faraji; Henrik Haraldsson; Karen G Ordovas; David Saloner
Journal:  AJR Am J Roentgenol       Date:  2015-06-23       Impact factor: 3.959

3.  The feasibility of 350 μm spatial resolution coronary magnetic resonance angiography at 3 T in humans.

Authors:  Ahmed M Gharib; Khaled Z Abd-Elmoniem; Vincent B Ho; Eszter Födi; Daniel A Herzka; Jacques Ohayon; Matthias Stuber; Roderic I Pettigrew
Journal:  Invest Radiol       Date:  2012-06       Impact factor: 6.016

Review 4.  Diagnostic accuracy of magnetic resonance angiography for detection of coronary artery disease: a systematic review and meta-analysis.

Authors:  Giovanni Di Leo; Erica Fisci; Francesco Secchi; Marco Alì; Federico Ambrogi; Luca Maria Sconfienza; Francesco Sardanelli
Journal:  Eur Radiol       Date:  2015-12-11       Impact factor: 5.315

5.  Additive value of 3T cardiovascular magnetic resonance coronary angiography for detecting coronary artery disease.

Authors:  Lijun Zhang; Xiantao Song; Li Dong; Jianan Li; Ruiyu Dou; Zhanming Fan; Jing An; Debiao Li
Journal:  J Cardiovasc Magn Reson       Date:  2018-04-30       Impact factor: 5.364

6.  Gadofosveset-based biomarker of tissue albumin concentration: Technical validation in vitro and feasibility in vivo.

Authors:  Owen C Richardson; Octavia Bane; Marietta L J Scott; Steven F Tanner; John C Waterton; Steven P Sourbron; Timothy J Carroll; David L Buckley
Journal:  Magn Reson Med       Date:  2014-02-11       Impact factor: 4.668

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.